SCHEMBL17213465

SCHEMBL17213465

CC(C)(C)OC(=O)Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@H]2OC(C)(C)O[C@H]21

nearest known ligand 0.79

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NT5E P21589 2/20 0.54
▸ PI4KA P42356 1/20 0.51
▸ PI4K2B Q8TCG2 1/20 0.51
▸ PI4K2A Q9BTU6 1/20 0.51
▸ PI4KB Q9UBF8 1/20 0.51
▸ ADORA3 P0DMS8 2/20 0.47
▸ ADORA2A P29274 1/20 0.45
▸ ADORA2B P29275 1/20 0.45
▸ ADORA1 P30542 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ LMNA P02545 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20699834 0.88 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL12379237 0.88 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL18571809 0.88 PI4KA (0.62) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL17920478 0.86 ADORA1 (0.61) NT5EADORA3ADORA2AADORA2BADORA1
SCHEMBL18526660 0.86 PI4KA (0.46) NT5EPI4KAPI4K2BPI4K2API4KB
SCHEMBL24835571 0.84 NT5E (0.58) NT5EADORA3ADORA2AADORA2BADORA1
SCHEMBL17213470 0.84 PI4KA (0.50) PI4KAPI4K2BPI4K2API4KBADORA3
SCHEMBL17920435 0.84 NT5E (0.70) NT5EADORA3ADORA2AADORA2BADORA1
SCHEMBL17920514 0.84 NT5E (0.70) NT5EADORA3ADORA2AADORA2BADORA1
SCHEMBL7203458 0.82 PI4KA (0.53) PI4KAPI4K2BPI4K2API4KBADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170044203-A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-02-16 — — US disclosed
US-20170044203-A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-02-16 — — US disclosed
WO-2015164573-A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER VITAE PHARMACEUTICALS, INC. (US) 2015-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044203-A1 PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER ENTPD5, ENTPD1, NT5E NT5E 3/4885PI4KA 1715/4885PI4K2B 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback